(TRGA)...This stock is under accumulation for news next week before the conference on Saturday with Michael Murphey. Buyers were hitting the offer all day and if you look at the time and sales for the day you will see a 10,000 block crossed on the offer at 3:59.39. I'm in at 3 3/8 and looking for a move over 4 early next week.
Thursday March 5, 1:35 pm Eastern Time
Company Press Release
Biotechnology Bridges Astonishing Science, Stocks At Investor Forums in San Diego, Bay Area March 14-15
SAN DIEGO--(BW HealthWire)---March 5, 1998--Biotechnology is the common platform where astonishing scientific discoveries germinate stock market profits at Informed Investors Forums in San Diego and Emeryville (across the Bay Bridge from San Francisco) on the mornings of Saturday, March 14, and Sunday, March 15, respectively.
Informed Investors, well known for bringing executives of exciting public companies to individual investors, has lined up top executives from 10 public biotech companies. Executives will talk about how their amazing scientific advances may eventually generate growing revenue and profits. Audio tapes of all presentations are available for the convenience of those unable to attend. Tapes are $25 for one forum, $45 for both. Any individual company tape costs $18.
There will be five companies at each Forum. The keynote speakers are outstanding -- biotech guru Michael Murphy in San Diego and prominent biotech analyst David Crossen in Emeryville. Each are well worth hearing as their opinions are closely followed by large investors throughout the world. Access Informed Investors' website at www.informedinvestors.com for full details about both events or call 800-992-4683. Cost to attend the Forums, which include a continental breakfast, is $15 prepaid and $20 at the door.
Murphy's talk is entitled ''Big Biotech Breakout in '98?'' Joining Murphy March 14 at the San Diego Forum (8 a.m.-12:30 p.m.) at the Mission Valley Radisson Hotel are executives at from Aurora Biosciences, Vical, Cypros Pharmaceutical, Genta Corp. and Trega Biosciences.The companies will give analyst-style presentations followed by a Q & A session.
On Sunday March 15 at the Bay Bridge/Hilton (8 a.m.-12:30 p.m.) in Emeryville, keynoter David Crossen, Managing Director and Senior Health Care Analyst at NationsBanc Montgomery Securities. headlines the Forum. His talk is entitled ''Are Biotechs A Good Buy In 1998?'' Joining Crossen are top executives at five biopharma companies -- Geron Corp., Gilead Sciences, Myriad Genetics, Shaman Pharmaceuticals and Xoma Corp.
Summaries of companies presenting in San Diego:
Aurora Biosciences (NASDAQ:ABSC - news) designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. For quarter ended 12/97, revenues were $7.3 million; after tax earnings were $1.8 million. 52-week range $9.375-$15.75.
Cypros (AMEX:CYP - news) develops and markets drug products for the hospital market. CYP currently has three products on the market, Glofil, Inulin and Ethamolin and expects to launch a new burn and wound care product in 1998. 52-week range $3.625-$6.125.
Genta Corp. (NASDAQ:GNTA - news) is a biopharma company whose strategy consists of building a product and technology portfolio that represents varying degrees of development risk and market potential, including Anticode (antisense) products intended to treat cancer at its genetic source, oral controlled-release drugs and other genomics opportunities. 52-week range $.75-$6.50.
Trega Biosciences (NASDAQ:TRGA - news) is a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. Warner-Lambert will purchase $1.5 million in Trega common stock. 52-week range $2.625-$7.625.
Vical (NASDAQ:VICL - news) is focused on the development of gene-based pharmaceutical product candidates for the prevention or treatment of cancer, infectious diseases and metabolic disorders. 52-week range $9.50-$18.125.
Summaries of companies presenting in San Diego:
Geron (NASDAQ:GERN - news) is focused on discovering and developing therapeutic and diagnostic products based upon common biological mechanisms underlying cancer and other age-related diseases. GERN focuses on telomeres, which are structures at the ends of chromosomes that the company has shown act as a molecular ''clock'' of cellular aging, and telomerase, an enzyme which appears to stop the ''clock.''
Gilead Sciences (NASDAQ:GILD - news) is developing an oral treatment for the flu. Hoffman La Roche is Gilead's development partner on GS4104. Gilead already markets an approved product for treating retinitus in AIDS patients, Vistide(TM), sold by Pharmacia & Upjohn. At year-end 1997, Gilead had $322 million in cash.
Myriad Genetics (NASDAQ:MYGN - news) is a genomics company and genetic testing firm focused on the discovery and commercialization of genes involved in major common disorders, including cancer, cardiovascular disease and central nervous system disorders.
Shaman Pharmaceutical (NASDAQ:SHMN - news) discovers and develops novel pharmaceutical products for major human diseases by isolating active compounds from tropical plants. Its lead compound, Provir, is in Phase III trials.
XOMA Corp. (NASDAQ:XOMA - news) Its lead BPI-derived product, Neuprex is currently being tested in two Phase III trials for severe pediatric meningococcemia patients and to prevent pulmonary complications in trauma patients suffering major blood-loss. Additional Neuprex clinical studies target infectious complications of liver surgery, intra-abdominal infections, and antibiotic-resistant lung infections in cystic fibrosis patients.
------------------------------------------------------------------------
Contact:
Informed Investors
Bob Taylor, Steve Chanecka or Tim Quast,
916/448-8222 or 800/992-4683
------------------------------------------------------------------------
More Quotes
and News:
Aurora Biosciences Corp (Nasdaq:ABSC - news)Cypros Pharmaceutical Corp (AMEX:CYP - news)Genta Inc (Nasdaq:GNTA - news)Geron Corp (Nasdaq:GERN - news)Gilead Sciences Inc (Nasdaq:GILD - news)Myriad Genetics Inc (Nasdaq:MYGN - news)Shaman Pharmaceuticals Inc (Nasdaq:SHMN - news)Trega Biosciences Inc (Nasdaq:TRGA - news)Vical Inc (Nasdaq:VICL - news)Xoma Corp (Nasdaq:XOMA - news)
Related News Categories: biotech, medical/pharmaceutical
------------------------------------------------------------------------
Help
------------------------------------------------------------------------
Copyright c 1998 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form.
See our Important Disclaimers and Legal Information.
Questions or Comments? |
